# The Senolytic Precision Problem

**ABSURD HEALTH INSTITUTE — MEDICAL CONCEPT PAPERS · VOLUME SIX · PAPER 37**

**Research series:** Engineering Longevity Medicine

**Article URL upon publication:** https://absurd.health/research/volume-six/the-senolytic-precision-problem/

**Abstract.** Senescent cells can protect against malignant proliferation and participate in wound repair, while persistent populations may contribute inflammatory pathology. This essay frames senolytics as a precision problem involving cell type, time, location and safety. It rejects universal elimination of senescence markers as a validated clinical rejuvenation strategy.

## Senescence is neither entirely good nor entirely bad

Cellular senescence can restrain proliferation of damaged cells and participate in wound healing, while persistent senescent populations can produce inflammatory and tissue-disrupting signals. Experimental work has shown that senescent cells appearing during cutaneous wound healing can support closure through PDGF-AA signaling. This challenges the casual idea that every cell bearing a senescence marker should be eliminated. Senolytic therapy therefore poses a selectivity problem: which cells, in which tissues, at which time should be removed or modified?

## The marker problem

There is no single universal marker that identifies every harmful senescent cell and excludes all beneficial ones. Cell-cycle arrest, secretory patterns, lysosomal changes and antiapoptotic dependencies vary by cell type and injury state. A therapy might eliminate a population contributing fibrosis while removing cells needed for local repair. Another drug might suppress harmful secretions without killing the cell, producing a different risk profile.

## Human clinical uncertainty

Early clinical studies are insufficient to establish broad anti-aging efficacy and long-term safety of senolytics. Many candidate agents have substantial off-target actions, and some combinations include drugs with established toxicities. Mouse improvements in frailty or inflammatory markers cannot be extrapolated as human lifespan gains. The evaluation must include wound healing, infection risk, hematologic effects and cancer surveillance over adequate time.

## The Institute's precision standard

Any senescence-directed intervention should specify a pathogenic cell population, evidence that its removal or modulation changes the disease process, and a meaningful outcome. Precision could mean timing a treatment after early repair, selecting a tissue or choosing a secretory program rather than indiscriminate killing. Evidence against the approach would be improvements in senescence markers without functional benefit, or worsened repair despite apparently successful cell clearance. The important idea is discrimination, not simply elimination.

## A clinical thought experiment

Removing every p16-positive cell from a wound could impair a transient reparative population even while eliminating a long-lived inflammatory population elsewhere might help. This is the precision problem in one sentence. A cell's marker does not fully identify its role, and its role can change as repair proceeds.

## What would discriminate among explanations

A useful senolytic study must define the targeted population, timing, evidence of actual elimination and relevant functional outcome. If an intervention lowers senescence markers but slows wound closure, the harm is mechanistically informative. Clinical claims must remain cautious because long-term outcomes in humans are not established for generalized anti-aging use.

## Selected scientific readings

- Demaria M et al. (2014). An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Developmental Cell. https://pubmed.ncbi.nlm.nih.gov/25499914/
- López-Otín C et al. (2023). Hallmarks of aging: An expanding universe. Cell. https://doi.org/10.1016/j.cell.2022.11.001

*This is an evidence-informed conceptual essay, not a systematic review, clinical trial, validated diagnostic instrument, or treatment recommendation.*